Incyte’s Retifanlimab Tests US FDA’s Tolerance For Low Response Rates In Accelerated Approval

US FDA advisory committee votes 13-4 to wait for Phase III data in anal cancer, expected in 2025.

Wait sign (source: shutterstock)
• Source: Shutterstock

The US FDA’s Oncologic Drugs Advisory Committee stayed focused on overall response rate when voting against the accelerated approval of Incyte Corporation’s retifanlimab for platinum-experienced anal cancer patients on 24 June.

Only four advisory committee members supported the accelerated approval pathway for retifanlimab, while 13 members agreed that a regulatory decision...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers